4.1 Article

Autonomic Dysfunction in Early Parkinson's Disease: Results from the United Kingdom Tracking Parkinson's Study

Journal

MOVEMENT DISORDERS CLINICAL PRACTICE
Volume 4, Issue 4, Pages 509-516

Publisher

WILEY
DOI: 10.1002/mdc3.12454

Keywords

Parkinson's disease; sexual dysfunction; autonomic dysfunction

Funding

  1. Parkinson's UK
  2. National Institute for Health Research (NIHR) DeNDRoN network
  3. NIHR Newcastle Biomedical Research Unit based at Newcastle upon Tyne Hospitals NHS Foundation Trust
  4. Newcastle University
  5. NIHR
  6. Bial Pharmaceuticals
  7. Cure Parkinson's Trust
  8. Rosetrees Trust
  9. MRC
  10. Birax
  11. EU
  12. Oxford Biomedica
  13. Biogen
  14. LCT
  15. Wellcome Trust
  16. MRC/Wellcome
  17. Michael J. Fox Foundation
  18. Medical Research Council UK
  19. Ipsen Fund
  20. Motor Neurone Disease Association
  21. Welsh Assembly Government
  22. PSP Association
  23. CBD Solutions
  24. Drake Foundation
  25. Teva
  26. AbbVie
  27. Boehringer Ingelheim
  28. GSK
  29. Brain Research Trust
  30. John Black Charitable Foundation
  31. European Union FP7
  32. National Institute for Health Research [NF-SI-0616-10011] Funding Source: researchfish
  33. Parkinson's UK [J-1101] Funding Source: researchfish

Ask authors/readers for more resources

BackgroundAutonomic dysfunction is common in the later stages of Parkinson's disease (PD), but less is known about its presence and severity in early disease. ObjectiveTo analyze features of autonomic dysfunction in recent onset PD cases, and their relationship to motor severity, medication use, other nonmotor symptoms (NMS), and quality-of-life scores. MethodsDetailed patient-reported symptoms of autonomic dysfunction were assessed in a multicenter cohort study in PD cases that had been diagnosed within the preceding 3.5 years. ResultsThere were 1746 patients (1132 males, 65.2%), mean age 67.6 years (SD 9.3), mean disease duration 1.3 years (SD 0.9), mean Movement Disorder Society Unified Parkinson's Disease Rating Scale motor score 22.5 (SD 12.1). Orthostatic symptoms were reported by 39.6%, male erectile dysfunction by 56.1%, and female anorgasmia by 57.4%. Sialorrhea was an issue in 51.4% of patients, constipation in 43.6%, and dysphagia in 20.1%. Autonomic features increased with higher modified Hoehn and Yahr stages (P < 0.001). The severity of autonomic dysfunction was associated with the postural instability gait difficulty motor phenotype [-coefficient 1.7, 95% confidence interval (CI) 0.7, 2.6, P < 0.001], depression (-coefficient 4.1, CI 3.0, 5.2, P < 0.001), and excess daytime sleepiness (-coefficient 3.1, CI 1.9, 4.2, P < 0.001). Dopamine agonists were the only drug class associated with greater autonomic dysfunction (P = 0.019). The severity of autonomic dysfunction strongly correlated with the presence of other NMS ( = 0.717, P < 0.001), and with poorer quality-of-life scores ( = 0.483, P < 0.001). ConclusionsAutonomic dysfunction is common in early PD. Autonomic dysfunction correlates with the presence of other NMS, and with worse quality of life.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available